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Abstract: Adrenal incidentaloma (AI) is a term applied to an accidentally discovered adrenal 
mass on imaging performed for reasons unrelated to adrenal pathology. The widespread applica-
tion of abdominal imaging procedure has resulted in an increased frequency of clinically silent 
adrenal masses. Although most AIs are nonfunctioning benign adenomas, a multidisciplinary 
approach with biochemical and radiological evaluation is needed to characterize these lesions and 
identify patients who are at high risk for hormonal or malignant evolution. Herein, we describe 
a case of a 69-year-old man with a pain at the base of right chest. On the basis of clinical evalu-
ation, biochemical analysis, as well as imaging procedures, a diagnosis of right adrenocortical 
carcinoma was made. The patient underwent medical treatment.
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Introduction
The widespread use of imaging, particularly computed tomography (CT) and magnetic 
resonance imaging (MRI), during diagnostic testing or treatment for many clinical 
conditions, has resulted in the identification of previously unsuspected adrenal lesions 
defined as adrenal incidentalomas (AIs).1,2 The assessment of AIs is aimed at deciding 
whether or not the tumor should be surgically removed,3 adrenalectomy being indicated 
in hormonal hypersecretory states (such as pheocromocytoma) and in potentially 
malignant lesions.4
Adrenal cortical carcinoma (ACC) is a rare and heterogeneous malignancy with 
incompletely understood pathogenesis and poor prognosis.5 ACC can be functional or 
nonfunctional with regard to hormone synthesis and clinical features.
We report the case of a 69-year-old man who was investigated for chest pain, with 
a right adrenal carcinoma identified by total body CT-scan and adrenal scintigraphy.
Case report
A 69-year-old male was admitted to the Geriatric Unit of Catanzaro Hospital due to 
the onset of chest pain since few days, without other symptoms. Clinical examina-
tion and review of systems as well as family medical history were unremarkable. On 
clinical examination we found only a mild hepatomegaly and a reduction of vesicular 
murmur. In the past medical history, he reported a moderate increase of systolic and 
diastolic blood pressure which was controlled by weight reduction, salt restriction, and 
pharmacological therapy (ramipril plus hydrochlorothiazide 5/25 mg one tablet/day). 
In the present admission, blood pressure was 140/80 mmHg and heart rate 110 beats Clinical Interventions in Aging 2010:5 32
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per min (bpm); patient’s body mass index was 36.36 Kg/m2. 
Chest X-ray was negative and electrocardiogram (ECG) 
recorded a sinus tachycardia. Biochemical analyses were 
normal (Table 1) as well as hormonal evaluation (Table 2). 
We found only high levels of fibrinogen (697 mg/dL), lac-
tate dehydrogenase (LDH; 758 U/L), α2-globulins (8.2%) 
(Table 1).
Following an abdominal ultrasound imaging (US), a 10-cm 
right adrenal lesion was identified (Figures 1 and 2). For this 
reason the patient underwent a total body CT-scan that revealed 
a 10-cm round, dense, heterogeneous enhancing lesion with 
irregular margins and inhomogeneous contrast enhancement of 
solid component after intravenous (iv) contrast medium. Local 
invasion (right liver lobe, renal hilus, and right diaphragm) 
and tumor extension into the inferior vena cava, as well as a 
tumor thrombus in the inferior vena cava and in the pulmonary 
arteries, were found. After 5 and 7 days, adrenal scintigraphy 
with iodocholesterol analogs showed a discordant pattern with 
absence of radiotracer uptake by the adrenal mass.
On the basis of these findings a diagnosis of “right adre-
nocortical carcinoma hormonally inactive” was made. Due 
to the invasive nature of the tumor we chose to put the patient 
on single agent mitotane.
Discussion
Incidentally discovered adrenal masses are found more fre-
quently, so that all clinicians need to be aware of their etiology 
since each case needs to be treated individually. Patient age, 
general conditions, and tumor extension have to be taken into 
account; they may suggest avoiding combination therapy with 
other cytotoxic drugs and surgical treatment.
The true prevalence of AIs is unknown. Much of the 
information quoted is derived from autopsy series, in which 
the prevalence of undiagnosed adrenal masses ranges from 
1.4% to 3%–6%.6 These results resemble those emerging 
from imaging studies, in fact, the prevalence of AIs in daily 
radiological practice is up to 5% of CT examination per-
formed for various reasons.7
However, the prevalence of incidentally discovered adre-
nal masses increases with age, accounting for less than 1% 
in patients aged younger than 30 years, approximately 7% 
Table 1 Biochemical evaluation
    NV
RBC 4.2 × 106/mm3 4.15–4.9 × 106/mm3
MCH 30 pg/cell 28–33 pg/cell
MCHC 34 g/dL 32–36 g/dL
MCV 88 µm3 86–98 µm3
HCT 44% 42%–52%
Hemoglobin 15 g/dL 13–18 g/dL
WBC 4.5 × 103/mm3 4.3–10.8 × 103/mm3
N 50% 45%–75%
L 20% 16%–45%
M 5% 4%–10%
e 2% 0%–7%
B 1% 0%–2%
Albumin 50% 50%–60%
α1-globulins 5% 4.2%–7.2%
α2-globulins 8.2% 6–7.8%
β-globulins 11% 9.3%–15%
γ-globulins 15% 13%–23%
AsT 20 U/L 0–35 U/L
ALT 24 U/L 0–35 U/L
Total bilirubin  
  Direct  
  Indirect
1 mg/dL  
0.3 mg/dL  
0.7 mg/dL
0.3–1.0 mg/dL  
0.1–0.3 mg/dL  
0.2–0.7 mg/dL
Glycemia 110 mg/dL 70–115 mg/dL
Cholesterol  
  LDL  
  HDL
220 mg/dL  
110 mg/dL  
60 mg/dL
220–239 mg/dL  
130 mg/dL  
50 mg/dL
Iron 80 µg/d 50–150 µg/d
Creatinine 1 mg/dL 0.8–1.2 mg/dL
BUN 15 mg/dL 10–20 mg/dL
Uric acid 6 mg/dL 2.5–8.0 mg/dL
Fibrinogen 697 mg/dL 200–450 mg/dL
sodium 140 meq/L 135–145 meq/L
Potassium 4 meq/L 3.5–5.0 meq/L
Calcium 9 mg/dL 9–10.5 mg/dL
LDH 758 U/L 100–190 U/L
Abbreviations: RBC, red blood cells; MCH, mean corpuscolar hemoglobin; MCHC, 
mean corpuscolar hemoglobin concentration; MCV, mean corpuscolar volume; HCT, 
hematocrit;   WBC, white blood cells; N, neutrophils; L, lymphocytes; M, monocytes; 
e, eosinophils; B, basophils; AsT, aspartate tranaminase; ALT, alanine transaminase; LDL, 
low density lipoproteins; HDL, high density lipoproteins; BUN, blood urea nitrogen; 
LDH, lactate dehydrogenase; NV, normal values.
Table 2 endocrine work-up
    NV
Cortisol 164.3 ng/mL 50–250 ng/mL
Renin 2 ng/mL/h 0.3–3.0 ng/ml/h
Aldosteron 10 µg/dL 5–19 µg/dL
ACTH 16 pg/mL 0–46 pg/mL
epinephrine 35 µg/d 50 µg/d
Norepinephrine 60 µg/dL 15–80 µg/dL
Overnight  
dexamethasone  
suppressor test
3 µg/dL 
 
5 µg/dL 
 
Abbreviations: ACTH, adrenocorticotropic hormone (corticotropin); NV, normal 
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Figure 1 Abdominal computed tomography shows a 10-cm right adrenal lesion.
between the fifth and the seventh decades, and showing peak 
incidence in the sixth decade.8
AI is not a single pathological entity. A recent study9 on 
the prevalence of incidental adrenal mass confirmed histo-
logically, shows that adenomas and myelolipomas are the 
most common lesions, whereas adrenocortical carcinoma 
is about 0.1%.
ACC is a rare malignancy (incidence 1–2 per million 
people) and radiologic prevalence is clearly related to the 
size of the tumor, accounting for 2% of tumors that are 
4 cm or less, 6% of tumors that are 4.1 to 6 cm, and 25% 
of tumors that are greater than 6 cm.10 Clinical presentation 
is heterogeneous and prognosis is variable but generally 
poor,11 in fact, overall, this neoplasia accounts for 0.02% to 
0.2% of all cancer-related deaths, with a median survival of 
18 months.
Women are more often affected than men (ratio 1:5);12 
this gender difference could be partly explained by the higher 
rate of diagnostic abdominal procedures recommended for 
women than men. The age distribution has two peaks: the 
first in childhood and the second in the fourth and fifth 
decade.13
Pathogenesis was incompletely understood, mutation at 
the 17p13 locus, including the p53 tumor suppressor gene, 
is observed in about 25% of cases;14 furthermore, altera-
tions of the 11p15 locus, leading to IGF-II overexpression 
are frequently observed15 compared to adenomas or normal 
adrenal cortex.
Patients present hormonal excess (virilization in women 
and gynecomastia and testis atrophy in men),16 Cushing’s 
syndrome, or local effect mass in hormonally inactive ACC 
(nausea, vomiting, abdominal and back pain).17
Biochemical screening for tumor hypersecretion as well 
as imaging evaluation is mandatory in all adrenocortical 
carcinomas to define the most correct approach. In fact, in 
stages I–II (localized or locally invasive tumor) complete 
tumor removal offers the best chance for cure by far,16 in 
particular a complete resection.18 In ACC sized more than Clinical Interventions in Aging 2010:5 34
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10 cm or with invasion of adjacent organs, local recurrence 
after surgery occurs in 40% of patients.19
Our patient had an advanced tumor and diagnosis was 
belated due to the absence of hormonal excess symptoms. 
Considering our patient’s age, general conditions (hyperten-
sion, sinus tachycardia, obesity), invasivity and prognosis 
of the neoplasm, and the possibility of intraoperative com-
plications, even after the negativity of biochemical work up 
(Table 2), we considered a medical therapy with mitotane.
Although adrenalectomy is the method of choice for the 
management of patients with ACC, being also compatible 
with a complete tumor resection in the presence of a tumor 
thrombus in the inferior vena cava,20 medical treatment 
should be considered as an alternative to adrenalectomy in 
elderly patients, in those unwilling to undergo surgery, and in 
patients with comorbid conditions that preclude surgery.21 In 
fact, while the presence of tumor thrombus may necessitate 
cardiac bypass technique, the prognosis of ACC still remains 
poor even after surgery with an overall five-year survival rate 
ranging between 16% and 38% in different series.22 Moreover, 
survival is clearly related to the extent of disease.23
Mitotane is the only adrenal-specific agent available for 
treatment of ACC, it exerts a specific cytotoxic effect on 
adrenocortical cells producing focal degeneration. In the first 
study on the efficacy of this therapy by Lim and colleagues,24 
seven of 18 patients with ACC showed significant tumor 
regression; even more favorable was the report by Lubitz and 
colleagues,25 which described tumor regression in 61% of 
patients. A recent clinical review by Allolio and colleagues5 
that analyzed the efficacy of mitotane treatment in advanced 
ACC, concluded that mitotane leads to an objective tumor 
regression in about 25% of cases.
Although a complete response (or even cure) in patients 
with advanced ACC is extremely rare, long-term survival 
has been reported;26 in fact our patient is alive and in good 
clinical conditions six months after surgery.
Figure 2 Abdominal computed tomography shows a 10-cm right adrenal lesion. Clinical Interventions in Aging 2010:5
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